This site contains promotional information intended only for healthcare professionals resident in Great Britain.

Visit Pfizer Medical site



Sign In or RegisterLog Out
Pfizer MedicinesTherapy AreasExplore ContentEventsVideosMaterialsLet’s ConnectStock Hub



AboutAboutHow XELJANZ worksXELJANZ in ActionCytokinesSignalling PathwaysDosingDosingDosing in RADosingPractical ConsiderationsDosing in UCDosingPractical ConsiderationsDosing in PsADosingPractical ConsiderationsDosing in pJIA and jPsADosingPractical ConsiderationsEfficacy & SafetyEfficacy & SafetySafety & TolerabilityOral SurveillanceAdverse EventsClinical Efficacy RAORAL Strategy Study DesignORAL Strategy Efficacy ResultsORAL Strategy Safety OutcomesClinical Efficacy UCOCTAVE Study DesignOCTAVE Sub GroupsOCTAVE InductionOCTAVE SustainPost-hoc AnalysesClinical Efficacy PsAOPAL Broaden & BeyondClinical efficacy pJIA and jPsAJIA-1 study designJIA-1 Efficacy ResultsJIA-1 Safety OutcomesReal World EvidenceReal World EvidenceReal World ExperienceWhy Real-World Data?RWE available for XELJANZEffectiveness in RWESafety in RWEDrug Maintenance in RWESupporting ResourcesSupporting ResourcesGRAPPA GuidelinesMaterialsVideos

XELJANZ® (tofacitinib citrate) Prescribing Information. Adverse event reporting can be found at the bottom of the page.


The immune system is a complex but coordinated system of cells, tissues, and soluble molecules that constitute the body's defence against invasion by non-self entities, including infectious and inert agents and tumour cells.

Immune homeostasis is the delicate balance of all immune responses used to fight disease.1 Immune homeostasis is affected by a number of different factors, both inherited and acquired:

Immune homeostasis naturally fluctuates over time, but in some cases the balance of pro-inflammatory and anti-inflammatory responses can shift to a new equilibrium, leading to diseases characterised by chronic immunosuppression or chronic inflammation.1

  • Chronic immunosuppression: too little inflammation may allow uncontrolled growth of pathogens or cancer cells
  • Chronic inflammation: too much inflammation may cause a variety of autoimmune conditions affecting one or several organ systems
Cytokines regulate many biological processes

Cytokines (greek, cyto- ‘cell’ & kinos – ‘movement’) are small molecules that mediate communication between cells resulting in:2

  • attraction of inflammatory and immune cells to a site within the body
  • activation of cells to release products that lead to tissue destruction

Cytokines may be classified according to function;2 however, the definition of cytokine function is ever-changing, with many cytokines playing multiple roles and falling into more than one category:

  • Inflammatory Response: The traditional paradigm of ‘pro-inflammatory’ and ‘anti-inflammatory’ cytokines has been challenged in recent years, and it should be noted that individual cytokines can exert diverse and even opposing effects, depending on the environment in which they are acting.3 Cytokines that are commonly seen as ‘pro-inflammatory’ cytokines include the TNF superfamily and IL-1 superfamily,3 amongst others. Examples of ‘anti-inflammatory’ cytokines include IL-4, IL-10, IL-13, IFN-α and TGF-β. Furthermore, specific cytokine receptors for IL-1, TNFα, and IL-18 also function as pro-inflammatory cytokine inhibitors.4
  • Chemotaxis: Chemotactic cytokines (‘chemokines’) stimulate the migration and activation of cells, especially phagocytic cells and lymphocytes. In the inflammatory response, they regulate the chemotaxis (movement in response to chemicals) of leucocytes, generally by attracting them to the site of inflammation.2 
  • Haematopoiesis: Haematopoietic cytokines are those known to be related to the formation of blood cells4; e.g. erythropoietin, G-CSF and GM-CSF.5
  • Growth and differentiation: Some cytokines are growth factors (e.g. G-CSF and GM-CSF), which promote growth and development by directing cell maturation and differentiation and by mediating maintenance and repair of tissues.4
Cytokines drive the inflammatory response in autoimmune diseases

In immune homeostasis, a complex network of cytokines balances pro-inflammatory and anti-inflammatory effects.6,7 Autoimmune diseases are, broadly speaking, the result of an imbalance between pro- and anti-inflammatory cytokines. In chronic autoimmune diseases, for example rheumatoid arthritis, joint destruction is driven by cytokine release.

* IL-1Rα , IL-18BP , IL-10 , TGF-β , IL-11 , IL-13.
** TNF , LT , IL-1β , IL-6 , IL-7 , IL-8 , IL-12, IL-17, IL-18 , IL-23 , IFN

TNF-tumour necrosis factor; IL-interleukin; IFN-interferon; TGF-B- transforming growth factor-beta; G-CSF-Granulocyte-colony stimulating factor; GM-CSF-Granulocyte/Macrophage-colony stimulating factor; LT-Leukotrienes; IL-18BP-interleukin-18 binding protein; Th-T-helper cell; T reg-T-regulatory cell.

Cytokine loops: Perpetuating the inflammatory signal

The chronic inflammatory state in autoimmune diseases occurs as a result of a continuing pro-inflammatory ‘cytokine loops’ whereby cytokines attract and stimulate immune cells to release more cytokines, which further stimulate production of cytokines. This process can lead to perpetuation or amplification of the inflammatory state.7


Crimeen-Irwin B, et al. Failure of immune homeostasis -- the consequences of under and over reactivity. Curr Drug Targets Immune Endocr Metabol Disord 2005;5(4):413-422.Murphy K, Weaver C. Janeway’s Immunobiology. 9th ed. New York, NY: Garland Science, Taylor & Francis Group, LLC; 2016.Muzes G et al. Changes of the cytokine profile in inflammatory bowel disease. World J Gastroenterol 2012:18(41):5848-5861Opal SM & DePalo VA. Anti-inflammatory cytokines. Chest 2000;117(4):1162-1172.Metcalf D. Hematopoietic cytokines. Blood. 2008: 11(2):485-491.Chizzolini C, et al. Cytokines in chronic rheumatic diseases: is everything lack of homeostatic balance? Arthritis Res Ther 2009; 11(5): 246-256.McInnes IB, Liew FY. Cytokine networks-towards new therapies for rheumatoid arthritis. Nat Clin Pract Rheumatol 2005; 1(1): 31-39.XELJANZ Risk Minimisation Programme (RMP) materials, including a Patient Alert Card, Prescriber Checklists and a Prescriber Brochure are available from Patients treated with XELJANZ should be given the Patient Alert Card.
PP-XEL-GBR-3124. August 2021
How XELJANZ works

Adverse events should be reported. Reporting forms and information can be found at or search 

for MHRA Yellow Card in Google Play or Apple App Store

Adverse events should also be reported to Pfizer Medical Information on 01304 616161

PfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign In or RegisterAccountSign Out

This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit

This website is brought to you by Pfizer Limited, a company registered in England 

and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ

Copyright © 2021 Pfizer Limited. All rights reserved.

VAT registration number GB201048427

PP-UNP-GBR-0596. April 2022
For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-3863. November 2021

You are now leaving PfizerPro​​​​​

​​​​​​​You are now leaving Links to external websites are provided as a resource to the viewer. This website is neither owned or controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site.​​​​​​​​​​​​​​

​​​​​​​PP-PFE-GBR-3858. November 2021​​​​​​​
You are now leaving PfizerPro
​​​​​​​You are now leaving Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site other than the information or other materials relating to ​​​​​Pfizer medicines or 
business which it has provided or reviewed.

PP-PFE-GBR-3859. November 2021

OK, We will need you to sign in before we can determine if you are aligned with a Pfizer promotional colleague.

If you have already registered with and select ‘yes’, you will be directed to the sign-in page where you will be required to enter your username and password.

Would you like to register or sign in now?